Sigachi Industries Navigates Q3 FY26 with Resilience and Strategic Focus

Sigachi Industries Limited, a prominent player in the pharmaceutical excipients sector, recently announced its financial results for Q3 FY26, revealing a challenging quarter marked by operational headwinds. The company reported a consolidated revenue from operations of INR 117.21 crore, a decrease of 15.92% year-on-year. This period saw a significant impact on profitability, with EBITDA plummeting by 82.83% year-on-year to INR 5.7 crore, and Profit After Tax (PAT) turning negative, down 100.08% year-on-year to INR (0.16) crore. The management attributed these results primarily to the aftermath of a fire accident at its Hyderabad plant and subsequent operational adjustments.

The decline in performance was largely driven by the temporary pause in operations at the Hyderabad facility, which necessitated the reallocation of overheads across other units and incurred higher material transportation costs and custom duties. Despite these challenges, the company's core business segments continued to contribute to revenue. The Microcrystalline Cellulose (MCC) segment remained the largest contributor, accounting for 70% of the revenue, followed by API at 12%, Operations and Management at 11%, and Allied Trades at 7%. Management emphasized that the demand for MCC remains strong, and the current lower share is due to production constraints rather than a lack of market interest.

Strategic Initiatives and Future Outlook

In response to the operational challenges, Sigachi Industries is undertaking several strategic initiatives aimed at strengthening its foundation and driving future growth. A key focus is the fast-tracked 12,000 MTPA capacity expansion at its Dahej-2 facility, with civil works already in progress. This expansion is expected to increase the company's total MCC capacity to 30,000 MTPA by Q3 FY27. Concurrently, an 1,800-ton CCS disintegrant facility at Dahej SEZ is also on track for commissioning in the same timeline, further diversifying its product offerings.

The company has decided not to reopen the Hyderabad plant due to its small size, location within city limits, and associated legal complexities. This decision allows Sigachi to concentrate resources on larger, more strategically located facilities like Dahej and Jhagadia. The management views the current period as one of reflection and action, focusing on rebuilding with stronger systems, deeper accountability, and long-term resilience, particularly in EHS systems and daily operating discipline.

R&D and Market Expansion

Sigachi is also making significant strides in its Research & Development efforts. A new API R&D Center in Hyderabad is now fully operational, focusing on critical API developments and analytical efforts. The company aims for six Certificate of Suitability (CEP) filings from this center, with the Metformin CEP already approved. This expansion into high-value excipients and API products is crucial for strengthening its regulated market readiness and moving up the value chain.

Management expects a return to normalcy in EBITDA margins after Q4 FY26, with double-digit EBITDA margins projected from FY28 onwards. They anticipate that the additional capacities coming online in FY27 will help absorb overheads and normalize operations, leading to steady revenue and margin growth in FY27 and FY28. Furthermore, the company has guided for approximately INR 250 crore in revenue from Cystic Fibrosis API after 12 months, indicating a promising new growth avenue.

Conclusion

Despite a challenging Q3 FY26, Sigachi Industries Limited demonstrates strategic clarity and a disciplined approach to execution. The company is leveraging its core strengths, including a strong global presence, diversified product portfolio, and robust R&D capabilities, to navigate current headwinds. With significant capacity expansions underway and a clear focus on high-value products, Sigachi is positioning itself for sustained growth and improved profitability in the coming years, reinforcing investor confidence in its long-term vision.